Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy.

Chang KC, Hung CH, Lu SN, Wang JH, Lee CM, Chen CH, Yen MF, Lin SC, Yen YH, Tsai MC, Tseng PL, Hu TH.

J Antimicrob Chemother. 2012 Nov;67(11):2766-72. doi: 10.1093/jac/dks269. Epub 2012 Aug 16.

PMID:
22899800
2.

Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy.

Omata M, Yoshida H, Shiratori Y.

Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S141-3. Review.

PMID:
16234063
3.

Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.

Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK.

Clin Gastroenterol Hepatol. 2010 Feb;8(2):192-9. doi: 10.1016/j.cgh.2009.10.026. Epub 2009 Oct 30. Review.

PMID:
19879972
4.

Treatment of chronic hepatitis C in Asia: when East meets West.

Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. Review.

PMID:
19335784
5.

Interferon-associated retinopathy during the treatment of chronic hepatitis C: a systematic review.

Raza A, Mittal S, Sood GK.

J Viral Hepat. 2013 Sep;20(9):593-9. doi: 10.1111/jvh.12135. Review.

PMID:
23910642

Supplemental Content

Support Center